Tango Therapeutics, Inc. (TNGX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 3.81B USD. 52-week range 6.69 to 34.39 USD. Data as of 2026-10-09.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of ...